Dr. Amrita Krishnan is a renowned hematologist specializing in multiple myeloma and hematopoietic cell transplantation. She serves as the Executive Medical Director of Hematology at City of Hope Orange County and is the Director of the Judy and Bernard Briskin Multiple Myeloma Center. After earning her medical degree from Albany Medical College, she completed her residency at the University of Rochester and fellowships at Harvard’s Beth Israel Hospital, Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, and City of Hope. She has been with City of Hope since 1996, where she has played a pivotal role in advancing myeloma research and treatment. Dr. Krishnan is an active leader in multiple national and international research groups, including the Multiple Myeloma Research Foundation and the International Myeloma Society. She has authored nearly 200 publications and continues to lead innovative clinical trials aimed at improving outcomes for patients with multiple myeloma.

Dr. Ajai Chari is a distinguished hematologist-oncologist specializing in plasma cell disorders, including multiple myeloma, amyloid light-chain (AL) amyloidosis, POEMS syndrome, plasmacytoma, and monoclonal gammopathies of undetermined significance (MGUS). He currently serves as a Professor of Medicine and Director of Clinical Research in the Multiple Myeloma Program at the University of California, San Francisco (UCSF). Dr. Chari earned his undergraduate degrees in Psychology and Biology from Stanford University, followed by a medical degree from the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). He completed his residency in internal medicine at Columbia University Medical Center and a fellowship in hematology and oncology at UCSF. Prior to his current role, Dr. Chari was an Associate Professor of Medicine and Director of Clinical Research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai in New York, where he also served as Associate Director of Clinical Research at the Mount Sinai Cancer Clinical Trials Office. His research focuses on developing novel chemotherapy regimens, including Phase 1 and 2 studies, and he has been the principal investigator for numerous investigator-initiated and industry-sponsored trials. Dr. Chari has published extensively on plasma cell disorders and has been invited to speak at major medical conferences worldwide.